Healthcare provider profile · identity verified

Lewis W Eirinberg, MD

Family Practice · OMAHA, NE · NPI 1851319743

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	698	198
Rosuvastatin Calcium	Rosuvastatin Calcium	272	83
Amlodipine Besylate	Amlodipine Besylate	269	80
Levothyroxine Sodium	Levothyroxine Sodium	248	64
Lisinopril	Lisinopril	217	56
Omeprazole	Omeprazole	215	69
Losartan Potassium	Losartan Potassium	198	53
Metformin Hcl	Metformin Hcl	193	48
Gabapentin	Gabapentin	171	38
Pantoprazole Sodium	Pantoprazole Sodium	147	36
Metoprolol Succinate	Metoprolol Succinate	143	42
Simvastatin	Simvastatin	130	34
Tamsulosin Hcl	Tamsulosin Hcl	124	35
Potassium Chloride	Potassium Chloride	121	29
Hydrochlorothiazide	Hydrochlorothiazide	113	34
Escitalopram Oxalate	Escitalopram Oxalate	100	30
Allopurinol	Allopurinol	95	22
Metoprolol Tartrate	Metoprolol Tartrate	92	20
Meloxicam	Meloxicam	87	34
Sertraline Hcl	Sertraline Hcl	87	19
Warfarin Sodium	Warfarin Sodium	85	suppressed
Atenolol	Atenolol	84	20
Benazepril Hcl	Benazepril Hcl	79	21
Eliquis	Apixaban	79	18
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	70	19
Alendronate Sodium	Alendronate Sodium	61	19
Jardiance	Empagliflozin	58	14
Pravastatin Sodium	Pravastatin Sodium	58	16
Furosemide	Furosemide	56	17
Farxiga	Dapagliflozin Propanediol	55	12
Metformin Hcl Er	Metformin Hcl	55	19
Zolpidem Tartrate	Zolpidem Tartrate	54	18
Trazodone Hcl	Trazodone Hcl	53	17
Fluticasone Propionate	Fluticasone Propionate	51	15
Duloxetine Hcl	Duloxetine Hcl	49	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	47	16
Fenofibrate	Fenofibrate	47	15
Bupropion Xl	Bupropion Hcl	43	13
Ezetimibe	Ezetimibe	42	13
Alprazolam	Alprazolam	38	11
Mounjaro	Tirzepatide	37	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	37	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	36	suppressed
Tramadol Hcl	Tramadol Hcl	34	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	33	17
Clopidogrel	Clopidogrel Bisulfate	32	11
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	32	suppressed
Benazepril-Hydrochlorothiazide	Benazepril/Hydrochlorothiazide	31	suppressed
Carvedilol	Carvedilol	31	11
Cefuroxime	Cefuroxime Axetil	31	27
Montelukast Sodium	Montelukast Sodium	29	suppressed
Prednisone	Prednisone	29	25
Tradjenta	Linagliptin	29	suppressed
Topiramate	Topiramate	28	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	26	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	26	suppressed
Ondansetron Hcl	Ondansetron Hcl	25	suppressed
Ropinirole Hcl	Ropinirole Hcl	25	suppressed
Citalopram Hbr	Citalopram Hydrobromide	24	suppressed
Divalproex Sodium	Divalproex Sodium	24	suppressed
Propranolol Hcl Er	Propranolol Hcl	24	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	23	suppressed
Valsartan	Valsartan	23	suppressed
Celecoxib	Celecoxib	22	suppressed
Irbesartan	Irbesartan	22	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	22	suppressed
Myrbetriq	Mirabegron	22	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	21	suppressed
Famotidine	Famotidine	21	suppressed
Mirtazapine	Mirtazapine	20	suppressed
Spironolactone	Spironolactone	20	suppressed
Finasteride	Finasteride	19	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	19	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	19	suppressed
Ramipril	Ramipril	19	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	19	suppressed
Sucralfate	Sucralfate	18	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	17	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	17	suppressed
Klor-Con M20	Potassium Chloride	17	suppressed
Trulicity	Dulaglutide	17	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	16	suppressed
Donepezil Hcl	Donepezil Hcl	16	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	16	suppressed
Ozempic	Semaglutide	16	suppressed
Tiadylt Er	Diltiazem Hcl	16	suppressed
Arnuity Ellipta	Fluticasone Furoate	15	suppressed
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	15	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	15	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	15	suppressed
Xarelto	Rivaroxaban	15	suppressed
Glimepiride	Glimepiride	14	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	14	suppressed
Tresiba Flextouch U-100	Insulin Degludec	14	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	14	suppressed
Diclofenac Sodium	Diclofenac Sodium	13	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	13	suppressed
Nabumetone	Nabumetone	13	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	13	suppressed
Solifenacin Succinate	Solifenacin Succinate	13	suppressed
Buspirone Hcl	Buspirone Hcl	12	suppressed
Clonidine Hcl	Clonidine Hcl	12	suppressed
Phenytoin	Phenytoin	12	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	12	suppressed
Terazosin Hcl	Terazosin Hcl	12	suppressed
Azithromycin	Azithromycin	11	11
Clonazepam	Clonazepam	11	suppressed
Doxepin Hcl	Doxepin Hcl	11	suppressed
Ibuprofen	Ibuprofen	11	suppressed
Januvia	Sitagliptin Phosphate	11	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Synthroid	Levothyroxine Sodium	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error